Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Preliminary phase I trial results show safety of bone marrow stem cells in children with TBI

Stem cells derived from a patient's own bone marrow were safely used in pediatric patients with traumatic brain injury, according to results of a Phase I clinical trial at The University of Texas Health Science Center at Houston.

10 Mar 2011

ISCO achieves major milestone in stem cell banking program

International Stem Cell Corporation, announced today the achievement of a major milestone in its efforts to establish a bank of immune-matched parthenogenetic stem cells in the United States by receiving the statutory approvals required to move forward with the next phase of its stem cell banking program.

10 Mar 2011

U.S. researchers who collaborate with international scientists more likely to receive greater recognition

U.S. researchers who collaborate with international scientists are more likely to have their work cited than peers who do not utilize overseas expertise, according to a new study released this week by Rice University's Baker Institute for Public Policy.

10 Mar 2011

New research identifies major surgeries that face risk of developing postoperative sepsis

Sepsis, a life-threatening bacterial infection of the blood, is an unwanted and costly complication to patients and the health care system. New research at UMDNJ-Robert Wood Johnson Medical School has identified major elective surgeries in which sepsis occurs most often post-procedure, along with extenuating conditions such as age, gender and type of hospital that increase the risk for sepsis.

10 Mar 2011

Professor utilizes $300,000 N.Y. grant to study adult neural stem cells

Rensselaer Polytechnic Institute Assistant Professor of Biomedical Engineering Deanna Thompson is utilizing more than $300,000 in New York state funding as part of the state stem cell research program, NYSTEM, to study adult neural stem cells.

10 Mar 2011

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Cell Therapeutics, Inc. today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma following discussions with the U.S. Food and Drug Administration's Division of Hematologic Products.

10 Mar 2011

Mother's poor or inadequate nutrition linked to overeating later in life

Providing further understanding of the link between low birth weights and obesity later in life, researchers found nutritionally deprived newborns are "programmed" to eat more because they develop less neurons in the region of the brain that controls food intake, according to an article published today in the journal, Brain Research.

10 Mar 2011

Cedars-Sinai earns excellence in 2010 adult heart transplants

The Cedars-Sinai Heart Institute and Comprehensive Transplant Center performed the most adult heart transplants of any U.S. medical center in 2010, according to government statistics released today.

10 Mar 2011

Trade name ‘The Stem Cell Group’ registered for Celulas Genetica

Emerging Healthcare Solutions, Inc. announced today that it registered a trade name, "The Stem Cell Group," for use in marketing and branding its subsidiary company, Celulas Genetica.

9 Mar 2011

U-M's North Campus Research Complex gets first lab-based scientists

The first laboratory-based researchers have moved into the University of Michigan's North Campus Research Complex (NCRC), bringing with them cutting-edge research that uses stem cells to create new heart muscle and focuses on the crucial squeezing action of the heart.

9 Mar 2011

Therapeutic potential of iPS cells may be limited by reprogramming errors and genomic instability

In the past few months, a slew of papers have indicated that the therapeutic potential of a promising type of stem cell, called induced pluripotent stem (iPS) cells, might be limited by reprogramming errors and genomic instability. iPS cells are engineered by reprogramming fully differentiated adult cells, often skin cells, back to a primitive, embryonic-like state.

9 Mar 2011

NHMRC awards $38.4M for cancer and blood cell research

Institute research into how cancer develops and blood cell production and function will today be awarded $38.4 million under the National Health and Medical Research Council's (NHMRC) program grants scheme.

9 Mar 2011

Autologous fat stem cell therapies for eternal life

Whereas formerly often only the symptoms of age were treated in cosmetic medicine, autologous stem cell-assisted regenerative therapies take a more comprehensive approach: the abundant stem cells in fat tissue are extracted and introduced in the body. The autologous stem cells then exert their regenerative power in the body where needed. Organs and tissues are regenerated and rejuvenated; even degenerative and chronic diseases are treatable.

9 Mar 2011

UCLA, Fibrocell Science enter scientific collaboration to advance cell therapy

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has entered into a scientific collaboration with University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity.

9 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

$100 million in grants for medical research announced

More than $100 million in grants was announced this Tuesday for an ambitious research project that will try to find what makes cancer so hard to beat. This project received $21.3 million from the National Health and Medical Research Council grants.

8 Mar 2011

Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions

Compugen Ltd. announced today positive animal model results for CGEN-25068, a novel peptide predicted and selected in silico to block a specific protein-protein interaction known to play an important role in various immune-related disease conditions.

8 Mar 2011

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.

8 Mar 2011

Now get a 3-D kidney printout to replace damaged kidneys: A regeneration science innovation

In what seems like science fiction, Dr. Anthony Atala, a regenerative medicine specialist at Wake Forest University, is pioneering the use of printing techniques to reconstruct and repair human flesh and organs. His basis is a combination of cultured human cells and scaffolding built or woven from organic material.

7 Mar 2011

Hadasit, Yissum license innovative regenerative membrane implant to RegeneCure

Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, and Hadasit Medical Research Services & Development Ltd., the technology transfer company of the Hadassah University Medical Center, today announced that they have licensed innovative regenerative membrane implant technology to RegeneCure, which will further develop and commercialize the technology for bone tissue engineering for applications in trauma, spine, and reconstructive cranial and facial orthopedics.

7 Mar 2011